Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study

被引：0
|
作者：
Marme, F. [1 ]
Hilpert, F. [2 ]
Welslau, M. [3 ]
Grabowski, J. P. [4 ,5 ]
Schneeweiss, A. [6 ,7 ]
Hartkopf, A. D. [8 ]
Becker, S. [9 ]
Runnebaum, I. [10 ]
Bauerschlag, D. [11 ]
Fasching, P. [12 ]
Brandi, C. [13 ]
Rehbein, J-K. [14 ]
Glowik, R. [15 ]
Sehouli, J. [16 ]
机构：
[1] UMM Univ Klinikum Mannheim, Dept Gynecol Oncol, Med Fak, Mannheim, Germany
[2] Krankenhaus Jerusalem, Mammazentrum, Hamburg, Germany
[3] Klinikum Aschaffenburg, Hamato Onkol Schwerpunktpraxis, Aschaffenburg, Germany
[4] Univ Klin Charite, Dept Gynecol, Berlin, Germany
[5] Campus Virchow Klinikum, Berlin, Germany
[6] Univ Hosp, Div Gynecol Oncol, Natl Ctr Tumor Dis NCT, Gynecol Oncol, Heidelberg, Germany
[7] German Canc Res Ctr, Heidelberg, Germany
[8] Univ Hosp Tuebingen, Ctr Womens Hlth Dept, Tubingen, Germany
[9] Goethe Univ Frankfurt Main, Dept Obstet & Gynecol, Campus Westend, Frankfurt, Germany
[10] Friedrich Schiller Univ Jena, Gynecol & Reprod Med, Jena, Germany
[11] Univ Hosp UKSH, Gynecol Oncol, Kiel, Germany
[12] Univ Klinikum Erlangen, Dept Gynecol & Obstet, Erlangen, Germany
[13] Agaples Med Versorgungszentrum Frankfurt gGmbH, Frauenheilkunde Gynakol, Frankfurt, Germany
[14] Stadt Krankenhaus Kiel GmbH, Frauenklin, Kiel, Germany
[15] AstraZeneca GmbH, Med Affairs, Hamburg, Germany
[16] Charite, Gynecol, Berlin, Germany
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1979
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
802P
引用
收藏
页码：S535 / S536
页数：2
相关论文
共 50 条
  • [41] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
    Ledermann, Jonathan
    Harter, Philipp
    Gourley, Charlie
    Friedlander, Michael
    Vergote, Ignace
    Rustin, Gordon
    Scott, Clare L.
    Meier, Werner
    Shapira-Frommer, Ronnie
    Safra, Tamar
    Matei, Daniela
    Fielding, Anitra
    Spencer, Stuart
    Dougherty, Brian
    Orr, Maria
    Hodgson, Darren
    Barrett, J. Carl
    Matulonis, Ursula
    LANCET ONCOLOGY, 2014, 15 (08): : 852 - 861
  • [42] HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND PATIENT-CENTRED OUTCOMES WITH OLAPARIB MAINTENANCE POST-CHEMOTHERAPY IN PATIENTS WITH GERMLINE BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)
    Friedlander, M.
    Gebski, V.
    Gibbs, E.
    Bloomfield, R.
    Hilpert, F.
    Wenzel, L. B.
    Joly, F.
    Eek, D.
    Rodrigues, M.
    Clamp, A.
    Penson, R.
    Provencher, D.
    Korach, J.
    Huzarski, T.
    Vidal, L.
    Salutari, V.
    Scott, C.
    Nicoletto, M. O.
    Tamura, K.
    Pujade-Lauraine, E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1941 - 1941
  • [43] Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
    Li, Huayi
    Peng, Zikun
    Zhu, Jianqing
    Zhao, Weidong
    Huang, Yi
    An, Ruifang
    Zheng, Hong
    Qu, Pengpeng
    Wang, Li
    Zhou, Qi
    Wang, Danbo
    Lou, Ge
    Wang, Jing
    Wang, Ke
    Kong, Beihua
    Xie, Xing
    Yin, Rutie
    Low, John
    Rozita, Abdul Malik
    Sen, Lim Chun
    Meng, Yong Chee
    Kiong, Kho Swee
    Liu, Jihong
    Liang, Zhiqing
    Lv, Weiguo
    Zhu, Yaping
    Hu, Weiguo
    Sun, Wei
    Su, Jingya
    Wang, Qiqi
    Zang, Rongyu
    Ma, Ding
    Gao, Qinglei
    BMC MEDICINE, 2024, 22 (01):
  • [44] OLAPARIB MONOTHERAPY VERSUS (VS) CHEMOTHERAPY FOR GERMLINE BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSR OC) PATIENTS (PTS): PHASE III SOLO3 TRIAL
    Penson, R. T.
    Valencia, R. V.
    Cibula, D.
    Colombo, N.
    Ill, C. L.
    Bidzinski, M.
    Kim, J. W.
    Nam, J. H.
    Madry, R.
    Hernandez, C. H.
    Mora, P.
    Ryu, S. Y.
    Milenkova, T.
    Lowe, E.
    Barker, L.
    Scambia, G.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A21 - A21
  • [45] Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?
    Lieberman, Howard B.
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 418 - 420
  • [46] Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study
    Majic, Ana
    Mise, Branka Petric
    Matkovic, Visnja
    Belac Lovasic, Ingrid
    Katic, Kristina
    Canjko, Ivana
    Frobe, Ana
    Bajic, Zarko
    Vrdoljak, Eduard
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [47] Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer
    Friedlander, Michael
    Banerjee, Susana
    Mileshkin, Linda
    Scott, Clare
    Shannon, Catherine
    Goh, Jeffrey
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 (04) : 323 - 331
  • [48] Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: Are some patients missing out?
    Moss, Haley
    Secord, Angeles Alvarez
    Perhanidis, Jessica
    Hawkes, Carol
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] OLAPARIB AS MAINTENANCE THERAPY AFTER PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PS-ROC). LATIN AMERICAN EXPERIENCE
    Mendana, A. L.
    Giornelli, G.
    Chacon, M.
    Costanzo, M. V.
    Puparelli, C. S.
    Petracci, F.
    Bruno, L.
    Casalnuovo, M. L.
    Lerzo, G.
    Recondo, G. J.
    Recondo, G.
    Tamburelli, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 771 - 771
  • [50] Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
    Zhong, Lixian
    Anh Thu Tran
    Tomasino, Taylor
    Nugent, Elizabeth
    Smith, Judith A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (12): : 1219 - 1228
12345